BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38588537)

  • 21. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of third-generation aromatase inhibitors on bone.
    McCloskey E
    Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer and osteoporosis.
    Cheung AM; Heisey R; Srighanthan J
    Curr Opin Endocrinol Diabetes Obes; 2013 Dec; 20(6):532-8. PubMed ID: 24468755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
    Sergi G; Pintore G; Falci C; Veronese N; Berton L; Perissinotto E; Basso U; Brunello A; Monfardini S; Manzato E; Coin A
    J Bone Miner Metab; 2012 Jul; 30(4):461-7. PubMed ID: 22160398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012-2015.
    Tamaki J; Fujimori K; Ikehara S; Kamiya K; Nakatoh S; Okimoto N; Ogawa S; Ishii S; Iki M;
    Osteoporos Int; 2019 May; 30(5):975-983. PubMed ID: 30648192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2018 Nov; 36(6):716-722. PubMed ID: 29116414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.
    Neuner JM; Shi Y; Kong AL; Kamaraju S; Smith EC; Smallwood AJ; Laud PW; Charlson JA
    J Cancer Surviv; 2018 Apr; 12(2):268-275. PubMed ID: 29243101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.
    Ramin C; May BJ; Roden RBS; Orellana MM; Hogan BC; McCullough MS; Petry D; Armstrong DK; Visvanathan K
    Breast Cancer Res; 2018 Nov; 20(1):134. PubMed ID: 30424783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
    Sato M; Ye W; Sugihara T; Isaka Y
    BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis.
    Lee YK; Lee EG; Kim HY; Lee Y; Lee SM; Suh DC; Yoo JI; Lee S
    J Korean Med Sci; 2020 Nov; 35(46):e403. PubMed ID: 33258332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson L; Lawrence D; Dawson C; Bliss J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.
    Becker T; Lipscombe L; Narod S; Simmons C; Anderson GM; Rochon PA
    J Am Geriatr Soc; 2012 Sep; 60(9):1761-7. PubMed ID: 22985145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study.
    Tzeng HE; Muo CH; Chen HT; Hwang WL; Hsu HC; Tsai CH
    BMC Musculoskelet Disord; 2015 May; 16():123. PubMed ID: 25989902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors.
    Antonini S; Pedersini R; Birtolo MF; Baruch NL; Carrone F; Jaafar S; Ciafardini A; Cosentini D; Laganà M; Torrisi R; Farina D; Leonardi L; Balzarini L; Vena W; Bossi AC; Zambelli A; Lania AG; Berruti A; Mazziotti G
    J Endocrinol Invest; 2024 Feb; 47(2):433-442. PubMed ID: 37592052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
    Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study.
    Scaturro D; de Sire A; Terrana P; Curci C; Vitagliani F; Falco V; Cuntrera D; Iolascon G; Mauro GL
    J Back Musculoskelet Rehabil; 2022; 35(1):207-212. PubMed ID: 34092604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone-Targeted Therapy in Early Breast Cancer.
    Jerzak KJ; Raphael J; Desautels DN; Blanchette PS; Tyono I; Pritchard KI
    Oncology (Williston Park); 2018 Nov; 32(11):562-9. PubMed ID: 30474104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.
    Branigan GL; Soto M; Neumayer L; Rodgers K; Brinton RD
    JAMA Netw Open; 2020 Mar; 3(3):e201541. PubMed ID: 32207833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.